• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓性肌萎缩症的出生患病率:爱沙尼亚的特定人群研究方法

The Birth Prevalence of Spinal Muscular Atrophy: A Population Specific Approach in Estonia.

作者信息

Sarv Siiri, Kahre Tiina, Vaidla Eve, Pajusalu Sander, Muru Kai, Põder Haide, Gross-Paju Katrin, Ütt Sandra, Žordania Riina, Talvik Inga, Õiglane-Shlik Eve, Muhu Kristina, Õunap Katrin

机构信息

Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.

Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia.

出版信息

Front Genet. 2021 Dec 22;12:796862. doi: 10.3389/fgene.2021.796862. eCollection 2021.

DOI:10.3389/fgene.2021.796862
PMID:35003227
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8729775/
Abstract

Rare diseases are an important population health issue and many promising therapies have been developed in recent years. In light of novel genetic treatments expected to significantly improve spinal muscular atrophy (SMA) patients' quality of life and the urgent need for SMA newborn screening (NBS), new epidemiological data were needed to implement SMA NBS in Estonia. We aimed to describe the birth prevalence of SMA in the years 1996-2020 and to compare the results with previously published data. We retrospectively analyzed clinical and laboratory data of SMA patients referred to the Department of Clinical Genetics of Tartu University Hospital and its branch in Tallinn. Fifty-seven patients were molecularly diagnosed with SMA. SMA birth prevalence was 1 per 8,286 (95% CI 1 per 6,130-11,494) in Estonia. Patients were classified as SMA type 0 (1.8%), SMA I (43.9%), SMA II (22.8%), SMA III (29.8%), and SMA IV (1.8%). Two patients were compound heterozygotes with an deletion with a novel single nucleotide variant NM_000344.3:c.410dup, p.(Asn137Lysfs*11). copy number was assessed in 51 patients. In Estonia, the birth prevalence of SMA is similar to the median birth prevalence in Europe. This study gathered valuable information on the current epidemiology of SMA, which can guide the implementation of spinal muscular atrophy to the newborn screening program in Estonia.

摘要

罕见病是一个重要的群体健康问题,近年来已经开发出了许多有前景的治疗方法。鉴于新型基因治疗有望显著改善脊髓性肌萎缩症(SMA)患者的生活质量,以及对SMA新生儿筛查(NBS)的迫切需求,爱沙尼亚需要新的流行病学数据来实施SMA NBS。我们旨在描述1996 - 2020年期间SMA的出生患病率,并将结果与之前发表的数据进行比较。我们回顾性分析了转诊至塔尔图大学医院临床遗传学部门及其在塔林分支机构的SMA患者的临床和实验室数据。57例患者被分子诊断为SMA。爱沙尼亚SMA的出生患病率为每8286例中有1例(95%置信区间为每6130 - 11494例中有1例)。患者被分类为0型SMA(1.8%)、I型SMA(43.9%)、II型SMA(22.8%)、III型SMA(29.8%)和IV型SMA(1.8%)。两名患者是复合杂合子,携带一种新型单核苷酸变异NM_000344.3:c.410dup,p.(Asn137Lysfs*11)的缺失。对51例患者进行了拷贝数评估。在爱沙尼亚,SMA的出生患病率与欧洲的出生患病率中位数相似。本研究收集了有关SMA当前流行病学的宝贵信息,可为爱沙尼亚将脊髓性肌萎缩症纳入新生儿筛查项目提供指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43df/8729775/d3a2e64fd85f/fgene-12-796862-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43df/8729775/92f1c6da91c8/fgene-12-796862-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43df/8729775/d3a2e64fd85f/fgene-12-796862-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43df/8729775/92f1c6da91c8/fgene-12-796862-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43df/8729775/d3a2e64fd85f/fgene-12-796862-g002.jpg

相似文献

1
The Birth Prevalence of Spinal Muscular Atrophy: A Population Specific Approach in Estonia.脊髓性肌萎缩症的出生患病率:爱沙尼亚的特定人群研究方法
Front Genet. 2021 Dec 22;12:796862. doi: 10.3389/fgene.2021.796862. eCollection 2021.
2
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis.意大利为期两年的脊髓性肌萎缩症 NBS 试点研究经验:制定分子诊断的具体指南和标准操作程序。
J Med Genet. 2023 Jul;60(7):697-705. doi: 10.1136/jmg-2022-108873. Epub 2022 Nov 22.
3
Incorporating Spinal Muscular Atrophy Analysis by Next-Generation Sequencing into a Comprehensive Multigene Panel for Neuromuscular Disorders.将下一代测序的脊髓性肌萎缩症分析纳入神经肌肉疾病的综合多基因panel 中。
Genet Test Mol Biomarkers. 2020 Oct;24(10):616-624. doi: 10.1089/gtmb.2019.0282. Epub 2020 Jul 23.
4
Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry.中国使用DNA质谱法进行脊髓性肌萎缩症的新生儿筛查。
Front Genet. 2019 Dec 17;10:1255. doi: 10.3389/fgene.2019.01255. eCollection 2019.
5
Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients.在一些脊髓性肌萎缩症(SMA)患者中,SMN1基因内的突变可能比SMN2的拷贝数对临床严重程度的影响更大。
Brain Dev. 2014 Nov;36(10):914-20. doi: 10.1016/j.braindev.2013.11.009. Epub 2013 Dec 17.
6
Novel Modification of a Confirmatory SMA Sequencing Assay that Can Be Used to Determine Copy Number.一种可用于确定拷贝数的确诊性脊髓性肌萎缩症测序检测方法的新型改良
Int J Neonatal Screen. 2021 Jul 21;7(3):47. doi: 10.3390/ijns7030047.
7
The analysis of the association between the copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein genes and the clinical phenotypes in 40 patients with spinal muscular atrophy: Observational study.40例脊髓性肌萎缩症患者生存运动神经元基因2和神经元凋亡抑制蛋白基因拷贝数与临床表型的相关性分析:观察性研究
Medicine (Baltimore). 2020 Jan;99(3):e18809. doi: 10.1097/MD.0000000000018809.
8
Association between the SMN2 gene copy number and clinical characteristics of patients with spinal muscular atrophy with homozygous deletion of exon 7 of the SMN1 gene.SMN1基因第7外显子纯合缺失的脊髓性肌萎缩症患者中SMN2基因拷贝数与临床特征的关联
Vojnosanit Pregl. 2015 Oct;72(10):859-63. doi: 10.2298/vsp140328072z.
9
Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?通过新生儿筛查诊断出患有脊髓性肌萎缩症和 4 个 SMN2 拷贝的婴儿 - 是机会还是负担?
J Neuromuscul Dis. 2020;7(2):109-117. doi: 10.3233/JND-200475.
10
Newborn screening for spinal muscular atrophy in Japan: One year of experience.日本脊髓性肌萎缩症的新生儿筛查:一年经验
Mol Genet Metab Rep. 2022 Aug 2;32:100908. doi: 10.1016/j.ymgmr.2022.100908. eCollection 2022 Sep.

引用本文的文献

1
A Brand-New Metal Complex Catalyst-Free Approach to the Synthesis of 2,8-Dimethylimidazo[1,2-]pyridazine-6-Carboxylic Acid-A Key Intermediate in Risdiplam Manufacturing Process.一种全新的无金属配合物催化剂方法用于合成2,8-二甲基咪唑并[1,2 -]哒嗪-6-羧酸——利司扑兰生产过程中的关键中间体。
Molecules. 2025 Jul 18;30(14):3011. doi: 10.3390/molecules30143011.
2
Diagnosing missed cases of spinal muscular atrophy in genome, exome, and panel sequencing data sets.在基因组、外显子组和基因组合测序数据集中诊断脊髓性肌萎缩症漏诊病例。
Genet Med. 2025 Apr;27(4):101336. doi: 10.1016/j.gim.2024.101336. Epub 2024 Dec 9.
3
Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China.

本文引用的文献

1
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go.全球脊髓性肌萎缩症新生儿筛查计划:现状与展望。
Neuromuscul Disord. 2021 Jun;31(6):574-582. doi: 10.1016/j.nmd.2021.03.007. Epub 2021 Apr 7.
2
Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010.欧洲新生儿筛查再审视:国际新生儿筛查学会对2010年以来现状与发展的观点
Int J Neonatal Screen. 2021 Mar 5;7(1):15. doi: 10.3390/ijns7010015.
3
Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years.
分析依库珠单抗治疗中国脊髓性肌萎缩症儿童的疗效和不良反应。
Brain Behav. 2024 Jul;14(7):e3630. doi: 10.1002/brb3.3630.
4
Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).《2024年全球新生儿血斑筛查现状:2020 - 2023年近期活动综合回顾》
Int J Neonatal Screen. 2024 May 23;10(2):38. doi: 10.3390/ijns10020038.
5
Diagnosing missed cases of spinal muscular atrophy in genome, exome, and panel sequencing datasets.在基因组、外显子组和基因panel测序数据集中诊断脊髓性肌萎缩症漏诊病例。
medRxiv. 2024 Jun 29:2024.02.11.24302646. doi: 10.1101/2024.02.11.24302646.
6
Changes in the Incidence of Infantile Spinal Muscular Atrophy in Shikoku, Japan between 2011 and 2020.2011年至2020年期间日本四国地区婴儿脊髓性肌萎缩症发病率的变化
Int J Neonatal Screen. 2022 Sep 26;8(4):52. doi: 10.3390/ijns8040052.
德国脊髓性肌萎缩症新生儿筛查:2 年后的临床结果。
Orphanet J Rare Dis. 2021 Mar 31;16(1):153. doi: 10.1186/s13023-021-01783-8.
4
Impact of a national population-based carrier-screening program on spinal muscular atrophy births.全国性人群携带者筛查项目对脊髓性肌萎缩症出生率的影响。
Neuromuscul Disord. 2020 Dec;30(12):970-974. doi: 10.1016/j.nmd.2020.10.005. Epub 2020 Oct 20.
5
Assessment of Spinal Muscular Atrophy Carrier Status by Determining Copy Number Using Dried Blood Spots.通过干血斑检测拷贝数评估脊髓性肌萎缩症携带者状态
Int J Neonatal Screen. 2020 May 29;6(2):43. doi: 10.3390/ijns6020043. eCollection 2020 Jun.
6
A Novel System for Spinal Muscular Atrophy Screening in Newborns: Japanese Pilot Study.一种用于新生儿脊髓性肌萎缩症筛查的新型系统:日本试点研究。
Int J Neonatal Screen. 2019 Nov 12;5(4):41. doi: 10.3390/ijns5040041. eCollection 2019 Dec.
7
Intragenic variants in the gene determine the clinical phenotype in 5q spinal muscular atrophy.该基因中的基因内变异决定了5q脊髓性肌萎缩症的临床表型。
Neurol Genet. 2020 Sep 1;6(5):e505. doi: 10.1212/NXG.0000000000000505. eCollection 2020 Oct.
8
Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations.新生儿脊髓性肌萎缩症筛查:安大略省检测和随访建议。
Can J Neurol Sci. 2021 Jul;48(4):504-511. doi: 10.1017/cjn.2020.229. Epub 2020 Oct 16.
9
Carrier frequency of SMN1-related spinal muscular atrophy in north Indian population: The need for population based screening program.北方印度人群中与 SMN1 相关的脊髓性肌萎缩症的携带频率:基于人群的筛查计划的必要性。
Am J Med Genet A. 2021 Jan;185(1):274-277. doi: 10.1002/ajmg.a.61918. Epub 2020 Oct 14.
10
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges.脊髓性肌萎缩症的新疗法:积极成果与新挑战
J Clin Med. 2020 Jul 13;9(7):2222. doi: 10.3390/jcm9072222.